Betahistine in vestibular vertigo and VIRTUOSO post-marketing observational program
https://doi.org/10.21518/2079-701X-2014-7-34-38
Abstract
The article tells about the specifics of vestibular vertigo and clinical manifestations of diseases commonly associated with dizziness. The efficacy, safety and good tolerability of betahistine hydrochloride (Betaserc) in various diseases characterized by vestibular vertigo is demonstrated. The design of the VIRTUOSO observational program to evaluate Betaserc effects in patients with vertigo in routine clinical practice, is described. The authors note that the study results will help to further assess the efficacy and safety of Betaserc and determine in which diseases the drug is most often used in Russia and Ukraine.
About the Authors
SV Morozova
Clinic and Department of ENT Diseases, First Moscow State Medical University named after I.M.Sechenov
Russian Federation
Russian Federation
VA Parfenov
Clinic and Department of Nervous Diseases and Neurosurgery
Russian Federation
Russian Federation
MV Zamergrad
Clinic and Department of Nervous Diseases and Neurosurgery
Russian Federation
Russian Federation
References
1. Brandt T. Vertigo. Its Multicensory Syndromes. London: Springer, 2000.
2. Борнштейн А., Лемперт Т. Головокружение: практический подход к диагностике и лечению М.: ГЭОТАР, 2010.
3. Парфенов В.А., Замерград М.В., Мельников О.А. Головокружение: диагностика и лечение, распространенные диагностические ошибки. М.: МИА, 2011.
4. Парфенов В.А., Абдулина О.В., Замерград М.В. Дифференциальная диагностика и лечение вестибулярного головокружения. Неврология, нейропсихиатрия, психосоматика, 2010, 2: 49-54.
5. Lacour M, Sterkers O. Histamine and betahistine in the treatment of vertigo. Elucidation of mechanisms of action. CNS Drugs, 2001, 15: 853-870.
6. Redon C, Lopez C, Bernard-Demanze L. Betahistine treatment improves the recovery of static symptoms in patients with unilateral vestibular loss. J Clin Pharmacol, 2011, 51: 538-548.
7. Mira E, Guidetti G, Ghilardi L et al. Betahistine dihydrochloride in the treatment of peripheral vestibular vertigo. Eur Arch Otorhinolaryngol, 2003, 260: 73-77.
8. Nauta JJ. Meta-analysis of clinical studies with betahistine in Meniere's disease and vestibular vertigo. Eur Arch Otorhinolaryngol, 2014, May, 271 (5): 887-97.
9. Fernandes CM, Samuel J. The use of piracetam in vertigo. S. Afr. Med.J., 1985, 68: 806-808.
10. Orendors-Fraczkowska K, Pospiech L, Gawron W. Results of combined treatment for vestibular receptor impairment with physical therapy and Ginkgo biloba extract (Egb 761). Otolaryngol. Pol., 2002, 56: 83-88.
11. Albera R, Ciuffolotti R, Di Cicco M et al. Double-blind, randomized, multicenter study comparing the effect of betahistine and flunarizine on the dizziness handicap in patients with recurrent vestibular vertigo. Acta Otolaryngol., 2003, 123: 588-593.
12. Мельников О.А., Замерград М.В. Доброкачественное позиционное головокружение. Лечащий врач, 2000, 1: 15-19.
13. Пальчун В.Т., Кунельская Н.Л., Ротермел Е.В. Диагноз и лечение доброкачественного пароксизмального головокружения. Вест Оториноларингол, 2007, 1: 4-7.
14. Korres SG, Balatsouras DG, Papouliakos S, Ferekidis E. Benign paroxysmal positional vertigo and its management. MedSciMonit, 2007, 13: 275-282.
15. Bhattacharyya N, Baugh RF, Orvidas L et al. Clinical practice guideline: benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg., 2008, 139: 47-81.
16. Guneri EA, Kustutan O. The effects of betahistine in addition to epley maneuver in posterior canal benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg., 2012, 146: 104-108.
17. Сагалович Б.М., Пальчун В.Т. Болезнь Меньера. М.: МИА, 1999.
18. Крюков А.И., Федорова О.К., Антонян Р.Г., Шеремет А.С. Клинические аспекты болезни Меньера. М.: Медицина, 2006.
19. Gates GA. Meniere's disease review 2005. J Am Acad Audiol, 2006, 17: 16-26.
20. Lezius F, Adrion C, Mansmann U, Jahn K, Strupp M. High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Meniere's disease: a case series. Eur Arch Otorhinolaryngol, 2011, 268: 1237-1240.
21. Strupp M, Hupert D, Frenzel C et al. Long-term prophylactic treatment of attacks of vertigo in Meniere's disease comparison of a high with a low dosage of betahistine in an open trial. Acta Oto-Laryngologica, 2008, 128: 520-524.
22. Dieterich M, Brandt T. Episodic vertigo related to migraine (90 cases): vestibular migraine? J Neurol, 1999, 246: 883-892.
23. Crevits L, Bosman T. Migraine-related vertigo: towards a distinctive entity Clin Neurol Neurosurg, 2005, 107: 82-87.
24. Eggers SD. Migraine-related vertigo: diagnosis and treatment. Curr Pain Headache Rep., 2007, 11: 217-226.
25. Celebisoy N, Gokpay F, Sirin H, Bipak N. Migrainous vertigo: clinical, oculographic and posturographic findings. Cephalalgia, 2008, 28: 72-77.
26. Парфенов В.А., Хасанова Д.Р. Ишемический инсульт. М.: МИА, 2012.
27. Oosterveld WJ. Betahistine dihydrochloride in the treatment of vertigo of peripheral vestibular origin. A double-blind placebo-controlled study. J Laryngol Otol, 1984, 98: 37-41.
28. Парфенов В.А., Бестужева Н.В. Диагностика и лечение головокружения в амбулаторной практике. Врач, 2012, 12: 18-21.
29. Jurkiewicz D, Kantor I, Usowski J. Assessment of betahistine dihydrochloride effectiveness in the treatment of disturbance of balance system, based on analysis of doctors and patients questionnaires results. Pol Merkur Lekarski, 2006, 21 (Suppl. 1): 3-12.
30. Benecke H, Perez-Garrigues H, Bin Sidek D, et al. Effects of betahistine on patient-reported outcomes in routine practice in patients with vestibular vertigo and appraisal of tolerability: experience in the OSVaLD study. Int Tinnitus J., 2010, 16: 14-24.
Review
For citations:
Morozova S, Parfenov V, Zamergrad M. Betahistine in vestibular vertigo and VIRTUOSO post-marketing observational program. Meditsinskiy sovet = Medical Council. 2014;(7):34-38. (In Russ.) https://doi.org/10.21518/2079-701X-2014-7-34-38
Views:
861
Email this article 